Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Leases (2019 - 2026)

Amphastar Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $45.6 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 8.91% year-over-year to $45.6 million; the TTM value through Dec 2025 reached $45.6 million, up 8.91%, while the annual FY2025 figure was $45.6 million, 8.91% up from the prior year.
  • Operating Leases for Q4 2025 was $45.6 million at Amphastar Pharmaceuticals, up from $39.4 million in the prior quarter.
  • Over five years, Operating Leases peaked at $45.6 million in Q4 2025 and troughed at $16.5 million in Q1 2021.
  • A 5-year average of $29.6 million and a median of $27.1 million in 2022 define the central range for Operating Leases.
  • Biggest five-year swings in Operating Leases: soared 54.82% in 2022 and later decreased 5.87% in 2023.
  • Year by year, Operating Leases stood at $24.7 million in 2021, then decreased by 4.08% to $23.7 million in 2022, then grew by 25.44% to $29.7 million in 2023, then soared by 40.91% to $41.9 million in 2024, then increased by 8.91% to $45.6 million in 2025.
  • Business Quant data shows Operating Leases for AMPH at $45.6 million in Q4 2025, $39.4 million in Q3 2025, and $39.0 million in Q2 2025.